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REPLY 
Sir, 
Kindly refer to the comments of Duggal 
and Nizamie on our paper. We are grateful to 
them for the interest shown in our paper. Our 
responses to their comments are given below-
I. The commetators have suggested that the 
PANSS should have been administered 
before and after the wash-out period. This has been 
clearly stated in the methodology section that 
THE EDITOR 
PANSS was done before and after wash-out and 
people showing 20% improvement were dropped. 
2. The concept of primary and secondary 
negative symptoms is still evolving and at the 
time the study was undertaken in 1996 this issue 
has not yet crystalised. That is why no attempt 
was made to differentiate primary from 
secondary negative symptoms. 
3. This study was done on patient consulting 
the clinic, on specified days and fulfilling the 
inclusion and exclusion criteria. Stability of 
symptomatology was not a criteria. However, 
chronic schizophrenic patients who had acute 
exacerbation were excluded. It has been also 
clearly stated in methodology thus the patients 
were more or less stable. 
4. There were 71 patients on 8 mg & 28 
(37%) of them developed EPS whereas, 
75 patients were on 6 mg & 37 (49%) developed 
EPS. Thus the dose of 6 and 8 mg did not show 
much difference on development of EPS in these 
patients. US/Canada study, also showed that 
patients on risperidone need same amount of 
anticholenergics as patients on haloperidol. 
5. Dose escalation was done as per 
recommended protocol at that time. It is possible 
that increase in autonomic instability was due to 
this reason. 
6. Clinical drug trial do recommend flexible 
dose design. In this study fixed dose design was 
used to study the acceptability of two 
recommended dosage. Earlier studies on 
risperidone have also used fixed dose design. 
The conclusions of any study have to 
be interpreted keeping in mind the strength and 
weaknesses of the study. A good study should 
allow readers to make independent conclusions. 
A.K. AGARWAL, MD.DPM.Head, Department of Psychiatry, 
KGs Medical College, Lucknow . 
RISPERIDONE INDUCED DYSTONIC 
REACTION AND AKATHISIA 
Sir, 
P.N. Suresh Kumar has reported acute 
dystonic reaction and akathisia in a patient who 
was given risperidone 3 rng b.i.d. in early part of 
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